Answers are grounded in this paper and cite their sources.
Background: Acute exacerbations of chronic obstructive pulmonary disease (AECOPD), frequently triggered by Streptococcus pneumoniae, are major contributors to disease progression and mortality. Although the polyamine spermine exhibits anti-inflammatory properties, its mechanistic role in AECOPD and the limitations imposed by impaired cellular transport remain poorly defined. Methods: We established in vivo AECOPD mouse models and in vitro alveolar macrophage systems. Integrated metabolomics and proteomics analyses were performed to identify key regulatory pathways. Molecular experiments, including ZFP36 knockdown and pyroptosis-associated protein analyses, were performed to investigate the role of ZFP36 in spermine-mediated inflammatory regulation. To overcome impaired transporter-dependent uptake, a macrophage-targeted nanodelivery system (MSNs/HA-Man) was engineered, and its therapeutic efficacy was evaluated in vivo. Results: Spermine levels were significantly reduced in COPD and AECOPD. Mechanistically, spermine treatment was associated with increased ZFP36 expression and reduced activation of the NLRP3/Caspase-1/IL-1β pyroptosis pathway. Importantly, metabolomic pathway enrichment suggested that SLC-mediated transport may be altered under pathological conditions, raising the possibility that cellular uptake of spermine could be affected. The enhanced therapeutic efficacy of the engineered MSNs/HA-Man nanocarrier may be partly attributable to CD44/CD206-mediated endocytosis, which could reduce dependence on transporter-mediated uptake and improve intracellular delivery compared with free spermine. Conclusions: Our findings suggest that the spermine–ZFP36 axis may represent an important regulatory pathway associated with inflammation in AECOPD. Moreover, macrophage-targeted nanodelivery may improve intracellular delivery efficiency and therapeutic efficacy. This study provides a novel framework integrating metabolic modulation with proof-of-concept nanomedicine strategy for the treatment of COPD exacerbations.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: